Skip to content
A Clinical Trial Failure Derails a Promising Technology episode artwork

Mar 21, 2024 44 min

A Clinical Trial Failure Derails a Promising Technology

from RARECast

In February, Synlogic cut 90 percent of its workforce as it ended a pivotal study of its lead experimental therapy to treat the rare, metabolic condition phenylketonuria. The decision came in response to results of an internal review that indicated the trial was unlikely to meet its primary endpoint. Synlogic, which had been developing a new class of therapies using synthetic biology, is now weighing its strategic options. We spoke to Neal Sondheimer, outgoing head of clinical for Synlogic and adjunct associate professor of pediatrics and molecular genetics for The Hospital for Sick Children in Toronto, about PKU, the treatment options for people with the condition, and the consequences of the surprising results from the Synlogic study.

Episode details come from the podcast's RSS feed.

Embed this episode

Neal Sondheimer, outgoing head of clinical for Synlogic and adjunct associate professor of pediatrics and molecular genetics for The Hospital for Sick Children in Toronto, discusses PKU, the treatment options for people with the condition, and the consequences of the surprising results from the Synlogic study.

Ready to play

A Clinical Trial Failure Derails a Promising Technology

0:00 44:08

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 44 minutes long.

When was this RARECast episode published?

This episode was published on March 21, 2024.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.